Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Current Deferred Revenue (2019 - 2020)

aTYR PHARMA (ATYR) has disclosed Current Deferred Revenue for 2 consecutive years, with $53000.0 as the latest value for Q3 2020.

  • For the quarter ending Q3 2020, Current Deferred Revenue fell 84.94% year-over-year to $53000.0, compared with a TTM value of $53000.0 through Sep 2020, down 84.94%, and an annual FY2019 reading of $208000.0, changed N/A over the prior year.
  • Current Deferred Revenue was $53000.0 for Q3 2020 at aTYR PHARMA, down from $201000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $630000.0 in Q1 2019 and bottomed at $53000.0 in Q3 2020.